On July 14, Mabwell Biopharma announced that the company's two denosumab injections 9MW0311 (Prolia® biosimilar, domestic trade name: Mylishu®) and 9MW0321 (Xgeva® biosimilar, domestic trade name: Mabwell®) signed a licensing and commercialization agreement with the Philippine pharmaceutical company UNILAB, INC. (hereinafter referred to as "UNILAB").

According to the agreement, UNILAB will be responsible for the registration and sales of the two products in the Philippines, and Mabwell Biopharma will be responsible for the development, production and commercial supply of the products.

It is reported that UNILAB is a leading pharmaceutical company in the Philippines, committed to the sales and promotion of high-quality new drugs in the Philippine market. According to IQVIA data, UNILAB ranks first in the pharmaceutical industry of the Association of Southeast Asian Nations with its production, registration and marketing capabilities. In August 2023, Mabwell Biopharma and UNILAB reached a strategic cooperation on adalimumab biosimilars, and the relevant products are currently being registered in the Philippines.

Hu Huiguo, Director, Senior Vice President and Secretary of the Board of Mabwell Biopharma, said that Mabwell Biopharma and UNILAB will adhere to the established cooperation model and vigorously promote the registration and commercial sales of denosumab in the Philippines. This cooperation will further expand Mabwell Biopharma's influence in the ASEAN market.

At present, Mabwell Biopharma has signed formal cooperation agreements on desutuzumab products in dozens of countries including Brazil, Colombia, Indonesia, Singapore, Pakistan, Thailand, Egypt, Saudi Arabia, etc., and the production site has passed the Colombian INVIMA GMP audit. 9MW0321 and 9MW0311 have published Phase III clinical research results in the authoritative journal "JAMA Oncology" and the internationally renowned journal "Expert Opinion on Biological Therapy" respectively.

https://finance.eastmoney.com/a/202507143456648045.html